NYU Langone Health: Glioma trials

The registry lists 10 Glioma studies with NYU Langone Health as lead sponsor. 3 are open to participants now and 2 have results posted.

Early Phase 1 1Phase 1 2Phase 2 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-LinacNot yet recruitingNCT07457307Phase 1
• Residual IDH1-Mutant Tumor Cell Quantification StudyNot yet recruitingNCT07219199Not applicable
• Concurrent XRD-0394 With Radiation Therapy for High Grade GliomasRecruitingNCT06829173Early Phase 1
• Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade AstrocytomasTerminatedNCT01338857Phase 2Results posted
• Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade GliomaTerminatedNCT01105702Phase 2Results posted
• Concurrent Azeliragon With Craniospinal IrradiationActive, not recruitingNCT06724926Phase 1
• Fitness and Nutrition in GliomaActive, not recruitingNCT06665373Not applicable
• Trial of IDH305 in IDH1 Mutant Grade II or III GliomaWithdrawnNCT02977689Phase 2
• Image Guided Therapy in the Treatment of GliomasTerminatedNCT01263821Not applicable
• Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade GliomaWithdrawnNCT00006263Phase 2